ADMA Biologics - Public Comps and Valuation Multiples

ADMA Biologics Overview

About ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Founded

2004

HQ

Employees

685

Website

admabiologics.com

Sectors

Biopharmaceuticals
BioTech

Financials

LTM Revenue $489M

LTM EBITDA $217M

EV

$3.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ADMA Biologics Financials

As of September 2025, ADMA Biologics reported last 12-month revenue of $489M and EBITDA of $217M.

In the same period, ADMA Biologics generated $270M in LTM gross profit and $153M in net income.

See ADMA Biologics valuation multiples based on analyst estimates

ADMA Biologics P&L

In the most recent fiscal year, ADMA Biologics reported revenue of $426M and EBITDA of $148M.

ADMA Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ADMA Biologics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$489M	XXX	$426M	XXX	XXX	XXX
Gross Profit	$270M	XXX	$220M	XXX	XXX	XXX
Gross Margin	55%	XXX	51%	XXX	XXX	XXX
EBITDA	$217M	XXX	$148M	XXX	XXX	XXX
EBITDA Margin	44%	XXX	35%	XXX	XXX	XXX
EBIT	$174M	XXX	$139M	XXX	XXX	XXX
EBIT Margin	36%	XXX	33%	XXX	XXX	XXX
Net Profit	$153M	XXX	$198M	XXX	XXX	XXX
Net Margin	31%	XXX	46%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for ADMA Biologics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $489M. EBITDA for the last twelve months was $217M. In the most recent fiscal year, ADMA Biologics achieved $426M in revenue and $148M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$489M	Analyst estimates available to subscribers	$426M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$270M	Analyst estimates available to subscribers	$220M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	55.1% gross margin	Analyst estimates available to subscribers	51.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$217M	Analyst estimates available to subscribers	$148M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	44.3% EBITDA margin	Analyst estimates available to subscribers	34.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$174M	Analyst estimates available to subscribers	$139M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	35.5% EBIT margin	Analyst estimates available to subscribers	32.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$153M	Analyst estimates available to subscribers	$198M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	31.2% net profit margin	Analyst estimates available to subscribers	46.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for ADMA Biologics

This financial data table provides comprehensive performance metrics for ADMA Biologics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

ADMA Biologics generated $489M in revenue over the last twelve months.
The company achieved $217M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $270M.
Net income over the last twelve months reached $153M.

Fiscal Year Performance

In the most recent fiscal year, ADMA Biologics reported $426M in total revenue.
Fiscal year EBITDA was $148M.
The company maintained a gross profit margin of 51.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 34.6%.
Net profit margin reached 46.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for ADMA Biologics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

ADMA Biologics Stock Performance

ADMA Biologics has current market cap of $3.4B, and EV of $3.4B.

Market Cap Evolution

ADMA Biologics Stock Data

As of October 17, 2025, ADMA Biologics's stock price is $14.

See ADMA Biologics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.4B	$3.4B	XXX	XXX	XXX	XXX	$0.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

ADMA Biologics Valuation Multiples

ADMA Biologics's trades at 8.0x EV/Revenue multiple, and 23.2x EV/EBITDA.

See valuation multiples for ADMA Biologics and 15K+ public comps

ADMA Biologics Financial Valuation Multiples

As of October 17, 2025, ADMA Biologics has market cap of $3.4B and EV of $3.4B.

Equity research analysts estimate ADMA Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ADMA Biologics has a P/E ratio of 22.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.4B	XXX	$3.4B	XXX	XXX	XXX
EV (current)	$3.4B	XXX	$3.4B	XXX	XXX	XXX
EV/Revenue	7.0x	XXX	8.0x	XXX	XXX	XXX
EV/EBITDA	15.8x	XXX	23.2x	XXX	XXX	XXX
EV/EBIT	19.7x	XXX	24.6x	XXX	XXX	XXX
EV/Gross Profit	12.7x	XXX	n/a	XXX	XXX	XXX
P/E	22.4x	XXX	17.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	31.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ADMA Biologics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

ADMA Biologics Margins & Growth Rates

ADMA Biologics's last 12 month revenue growth is 24%

ADMA Biologics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.

ADMA Biologics's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ADMA Biologics's rule of X is 105% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for ADMA Biologics and other 15K+ public comps

ADMA Biologics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	24%	XXX	22%	XXX	XXX	XXX
EBITDA Margin	44%	XXX	35%	XXX	XXX	XXX
EBITDA Growth	50%	XXX	570%	XXX	XXX	XXX
Rule of 40	26%	XXX	59%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	105%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	19%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial